Nutra Pharma Corp. (OTC BB: NPHC) stock declined during 2010 from February 18 high of $0.67 to July 8 low of $0.15, despite strong growth in revenues during Q4 2009 and Q1 2010. Nutra Pharma’s shares soared 53% on July 26 to $0.26, after the Company announced its upcoming television and radio campaign for over-the-counter pain reliever, Cobroxin. The trading volume exceeded $255,000 on July 26, which was well above the average of approximately $50,000 registered for the last three months period.
Nutra Pharma is a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV).
Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Cobroxin, the first over-the-counter pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain; Nyloxin OTC pain reliever to treat Stage 2 pain; and Nyloxin Rx, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain.
During the first quarter of 2010, Nutra Pharma generated revenues of $864,424 from Cobroxin sales, compared to approximately 590,000 in Q4 2009. The Company is currently focused on expanding brand awareness for its over-the-counter pain relievers, Cobroxin, Nyloxin OTC and Nyloxin Rx by seeking out additional international distribution partners for Nyloxin branded pain relievers, assisting XenaCare Holdings Inc., Nutra Pharma’s U.S. Cobroxin distributor, with the creation of marketing and advertising materials including print advertisements, television commercials, packaging enhancements and television interviews; and coordinating the ongoing drug registration process in Europe, Canada, Brazil and Colombia, including reviewing distributor candidates within those territories.
Cobroxin was introduced, through e-commerce websites, during the last quarter of 2009. The product has been reviewed and accepted by 40% of the 105,000 retail stores selling healthcare products across the United States, as reported by Chain Drug Review magazine. XenaCare reported that Corboxin is already available in 22 retail networks all over the U.S.
XenaCare is currently rolling out an U.S. wide advertising campaign to support the rapidly growing network of retailers carrying Cobroxin. The advertising campaign, which is scheduled to begin on July 28, 2010, and run through December 2010, will consist of 2,515 television commercials in 60, 30 and 10 second spots appearing on major cable stations such as: CNN, Fox News, Food, Travel, ESPN, USA, Lifetime, CNBC, Comedy Central, AMC, History, Discovery, Fox Sports, Headline News (HLN), and Home and Garden. The commercials will also appear on the major power stations NBC, CBS, and ABC. In addition the campaign will also include 770 radio spots during drive-time hours in Tampa, Atlanta, New York, Los Angeles and Houston.
XenaCare has already tested the television commercial on the Hallmark channel in June and in one week it doubled the Corboxin sales at several major retailers. With a total household reach of 100 million, this campaign could be equally successful in pulling Cobroxin sales through the current distribution chain.
Besides, the Company is actively promoting the Nyloxin line of pain relievers. On June 10, Nutra Pharma announced that Grupo Farmaceutico de Tijuana (GFT) has become the exclusive Mexican distributor for the Company’s Nyloxin-branded pain relievers, Nyloxin OTC and Nyloxin Rx. In addition to partnering with GFT for Nyloxin distribution throughout Mexico, Nutra Pharma has recently announced its agreement with leading healthcare products distributor, Henry Schein, which ranks 339 on the Fortune 500 list, for distribution of Nyloxin in the United States.
The latest developments clearly support the strong appreciation that the Company’s stock witnessed on July 26. However, there are still doubts concerning the effectiveness of Corboxin and Nyloxin product lines, which could require additional independent tests to support the extraordinary claims that Nutra Pharma made about these products. Accordingly, the increased product visibility as well as the solid revenue stream that emerged as a result of advertising campaign could be altered by eventual speculations due to lack of independent clinical evidence.
About BeaconEquity.com
BeaconEquity.com is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or “penny stock” market, which has traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
Beacon Equity Group Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Beaconequity.com is a wholly owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
- Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
- See today’s top stock picks and market analysis
- Want more? Check out the message board buzz for these stocks
- See what newsletters are recommending these stock picks
- Get breaking news alerts on these stocks: http://thestockmarketwatch.com/
- This newsletter has been helping traders make a killing on these stocks. Click here for a 25% discount offer.
About BeaconEquity.com
BeaconEquity.com is committed to producing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
Beacon Equity Group Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Beaconequity.com is a wholly-owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
